The FDA clearance allows Edesa to expand an ongoing placebo-controlled study of the CXCL10 antibody EB06 to US sites, with topline data expected in the fourth quarter of 2027.
|Videos|July 21, 2022
How Ruxolitinib Will Change the Future of Vitiligo Treatment
Author(s)Kaitlyn Bader, Associate Editor
Pearl Grimes, MD, FAAD, and director of the Grimes Center of Medical and Aesthetic Dermatology and the Vitiligo & Pigmentation Institute of Southern California in Los Angeles, explains why the FDA approval of ruxolitinib cream 1.5% is monumental in the treatment of vitiligo.
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Tildrakizumab for Active Psoriatic Arthritis
2
FAQ: Remibrutinib (Rhapsido) Becomes First FDA-Approved Treatment for a Chronic Inducible Urticaria
3
Improving Early Identification and Escalation of HS
4
Dupilumab and Catch-Up Growth in Children With Severe Atopic Dermatitis
5